Unrecognized Fibrinogen A alpha-Chain Amyloidosis: Results From Targeted Genetic Testing

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Tavares, I (Author) Other; João Paulo Oliveira (Author) FMUP; Pinho, A (Author) Other; Moreira, L (Author) Other; Rocha, L (Author) Other; Santos, J (Author) Other; Pinheiro, J (Author) Other; costa, pp (Author) ICBAS; Lobato, L (Author) Other

Journal

Title: American Journal of Kidney Diseases

Vol. 70

Pages: 235-243

ISSN: 0272-6386

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 5 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00R-AMN

DOI: 10.1053/j.ajkd.2017.01.048

Abstract (EN): Background: Fibrinogen A a-chain (AFib) amyloidosis results from autosomal-dominant mutations in the gene encoding AFib (FGA). Patients with this disorder typically present with proteinuria. Isolated cases of AFib amyloidosis, carrying the FGA p.Glu545Val variant, were identified in the district of Braga, in northwest Portugal. This observation led us to hypothesize that this disorder might be an unrecognized cause of kidney disease in that region and prompted us to carry out targeted genetic testing for the p.Glu545Val variant in the local hemodialysis population and family members of identified cases. Study Design: Case series. Setting & Participants: 3 groups of participants: (1) kidney biopsy registry, n = 4; (2) hemodialysis facility, n = 122 of 267 patients; and (3) genetically at-risk individuals; n = 69 of 167 family members. Outcomes: Kidney disease, kidney disease progression, and survival. Results: The p.Glu545Val variant was identified in all 4 patients of the biopsy registry, 12 of 122 (9.8%) hemodialysis patients tested, and 34 of 69 (49%) relatives tested. These 50 cases belonged to 13 unrelated families with kidney disease or amyloidosis identified in 61% of probands. 35 individuals presented with hypertension at a mean of 51.0 +/- 10.4 years. Of these, 30 developed kidney disease at a mean of 56.7 +/- 12.0 years, and 21 initiated dialysis therapy at a mean of 61.4 +/- 11.3 years. Heart, liver, spleen, colon, and ileum were involved along the progression of the disease. Kidney disease was formerly attributed to hypertension in 25% of patients with AFib amyloidosis undergoing hemodialysis. Limitations: Retrospective data collection for patients with amyloidosis previously diagnosed. Conclusions: AFib amyloidosis appears to be an under-recognized disorder in Braga, Portugal, where we found a high frequency of the FGA p.Glu545Val variant. Due to the nonspecific nature of its major clinical features, the diagnosis of AFib amyloidosis should have a high index of suspicion, particularly in populations in which hypertension is prevalent. (C) 2017 by the National Kidney Foundation, Inc.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9